Andrew M. Rogers

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.4K citations

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu et al. · Cancer Cell · 2010 · 1.1K citations · Full text

Signal Transduction, Met Amplification, Medicine +6

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto et al. · Science Translational Medicine · 2011 · 658 citations

Cetuximab Sensitivity, Oncology, Erbb2 Signaling +15

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

Dalia Ercan, Chunxiao Xu, Masahiko Yanagita et al. · Cancer Discovery · 2012 · 290 citations · Full text

Noninvasive Detection of <i>EGFR</i> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

Yanan Kuang, Andrew M. Rogers, Beow Y. Yeap et al. · Clinical Cancer Research · 2009 · 227 citations · Full text